Nanoscope Expands Global Footprint with Saudi Orphan Drug Designation for MCO-010
Event summary
- Nanoscope Therapeutics received Orphan Drug Designation in Saudi Arabia for MCO-010, its lead therapy for inherited retinal dystrophies (IRDs).
- MCO-010 has now secured regulatory designations across the U.S., Japan, Europe, and the Middle East.
- The therapy is in late-stage development, with a rolling Biologics License Application (BLA) submission underway in the U.S.
- Nanoscope plans to initiate a Phase 3 trial for Stargardt disease and a Phase 2 program for geographic atrophy in 2026.
The big picture
Nanoscope's latest designation underscores its strategy to position MCO-010 as a first-in-class, disease-agnostic optogenetic therapy. The company is building one of the most comprehensive global development strategies in the space, targeting a broad range of inherited retinal dystrophies. With positive Phase 2b/3 trial results for retinitis pigmentosa and ongoing regulatory progress, Nanoscope is poised to potentially set a new standard of care for retinal degenerative diseases.
What we're watching
- Regulatory Momentum
- Whether Nanoscope can sustain this pace of global regulatory approvals to accelerate MCO-010's commercialization.
- Clinical Execution
- The success of the upcoming Phase 3 trial for Stargardt disease and Phase 2 program for geographic atrophy in 2026.
- Market Access
- How the Saudi designation will impact Nanoscope's ability to penetrate emerging markets with limited access to advanced retinal treatments.
Related topics